SpineThera

SpineThera is a clinical-stage pharmaceutical company based in Plymouth, United States, focused on improving the treatment of radicular leg pain, commonly known as sciatica. The company's central proposition is that back pain — and specifically lumbar radicular pain — is among the most common causes of disability in the United States and globally, and one of the most expensive indications in healthcare, yet there is no FDA-approved drug for epidural injection to treat it. Patients with this condition frequently require repeated epidural corticosteroid injections to achieve and maintain adequate pain relief, a cycle that SpineThera aims to break. SpineThera's lead asset is SX600, a novel formulation of dexamethasone built on the company's Faros™ technology. Faros™ is designed to provide months-long sustained release of dexamethasone from a single epidural injection, potentially replacing the need for repeated procedures. According to the company, a Phase 2 clinical trial showed a clinically meaningful and durable reduction in lumbar radicular pain after a single epidural injection of SX600, which SpineThera highlights as evidence of potential best-in-class efficacy. SpineThera is presented publicly as part of Frenelle Pharma, whose website hosts the SpineThera program pages and describes the company's mission to improve efficacy, durability of response, and reduce side effects while prioritizing equal access for patients. Frenelle Pharma's leadership team includes Chief Executive Officer and Chairman of the Board Jeffrey Missling, Chief Medical Officer Dr. Lee Techner, Chief Financial Officer Mark Payne, Vice President of Research & Development Emily Meyering, Australian Medical Director William Houghton, and Head of Communications and Administration Cassie Miller, with a board that includes John Foster, Doug Drysdale, Wayne Kelly, and Dr. Shaheen Lakhan. As a clinical-stage company, SpineThera does not yet market an approved product; its value rests on the SX600 development program and the Faros™ sustained-release platform. The company's positioning is centered on the unmet need in interventional pain management, where repeated steroid injections are the current standard and no epidural product has received FDA approval for lumbar radicular pain. SpineThera's stated goal is to deliver durable, single-injection relief that could reduce the burden of repeated procedures on patients and the healthcare system.

SpineThera is a clinical-stage pharmaceutical company located in Plymouth, United States, dedicated to improving the lives of patients suffering from radicular leg pain, commonly referred to as sciatica. The company was built around a specific and well-documented unmet need in interventional pain medicine: back pain, including lumbar radicular pain, is described by the company as the most common cause of disability within the United States and globally, and as the most expensive indication in healthcare. Despite this burden, there is no FDA-approved drug for epidural injection to treat lumbar radicular pain, and patients commonly require repeated epidural corticosteroid injections to achieve and maintain adequate pain relief. SpineThera's response to this problem is its lead asset, SX600, a novel formulation of dexamethasone that uses the company's Faros™ technology to provide months-long sustained release of the drug from a single epidural injection. The therapeutic hypothesis is that a single procedure delivering sustained drug exposure can produce durable pain relief and reduce the need for repeat injections. The company reports that a Phase 2 clinical trial demonstrated a clinically meaningful and durable reduction in lumbar radicular pain after a single epidural injection of SX600, which it presents as highlighting the potential for best-in-class efficacy. In its current public presentation, SpineThera appears as part of Frenelle Pharma, whose website carries the SpineThera program pages and describes the company's mission to improve efficacy and durability of response while reducing side effects, with a stated commitment to equal access and putting patients first. Frenelle Pharma's disclosed leadership includes Chief Executive Officer and Chairman of the Board Jeffrey Missling, Chief Medical Officer Dr. Lee Techner, Chief Financial Officer Mark Payne, Vice President of Research & Development Emily Meyering, Australian Medical Director William Houghton, and Head of Communications and Administration Cassie Miller, alongside board members John Foster, Doug Drysdale, Wayne Kelly, and Dr. Shaheen Lakhan. Because SpineThera remains a clinical-stage enterprise, its history to date is primarily a development history rather than a commercial one: the advancement of SX600 through clinical testing, the application of the Faros™ sustained-release platform, and its integration into the Frenelle Pharma organization. No approved products, manufacturing scale-up, or commercial launches are documented in the available evidence.

• SpineThera is described as a clinical-stage company based in Plymouth, United States, developing treatments for radicular leg pain (sciatica).

• Lead asset SX600, a sustained-release dexamethasone formulation using Faros™ technology, is developed for lumbar radicular pain.

• A Phase 2 clinical trial of SX600 reports clinically meaningful and durable reduction in lumbar radicular pain after a single epidural injection.

• SpineThera is presented publicly as part of Frenelle Pharma, whose website hosts the SpineThera program pages.

Clinical-stage developer of a single-injection, months-long sustained-release epidural corticosteroid for lumbar radicular pain (sciatica), targeting an indication with no FDA-approved epidural drug.

• SX600

  A novel formulation of dexamethasone using Faros™ technology, developed for lumbar radicular pain (sciatica) and intended to provide months-long sustained release from a single epidural injection.

• Faros™

  SpineThera's sustained-release technology platform used to deliver months-long release of dexamethasone from a single epidural injection.

1. 1SpineThera | Frenellefrenellepharma.com
2. 2About | Frenellefrenellepharma.com
3. 3SpineThera (United States) - Wikidatawikidata.org
4. 4SpineThera official websitespinethera.com